Physician profile
Michelle E Bloom
NPI 1952569873
$165,956.99
in general payments reported to CMS, 2019-2025
13 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $3,649 · 2021: $40K · 2022: $47K · 2023: $14K · 2024: $1,002 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,518 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,200 · Food and Beverage: $1,783 · Long Term Medical Supply Or Device Loan: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,518.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,200.00 |
| Food and Beverage | $1,782.94 |
| Long Term Medical Supply Or Device Loan | $1,180.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $55,978.70 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $40,369.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $36,484.40 | 2021-2025 | Farxiga, Calquence, Wainua |
| Vifor Pharma, INC. | $30,134.29 | 2019-2021 | |
| Abbott Laboratories | $2,128.78 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Alnylam Pharmaceuticals INC. | $362.48 | 2023-2025 | Amvuttra, Onpattro |
| Scpharmaceuticals INC. | $184.73 | 2023-2025 | |
| Abiomed | $90.60 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.89 | 2020-2024 | Lifevest |
| Sumitomo Pharma America, INC. | $69.11 | 2025 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $44.17 | 2022-2023 | Eliquis, Camzyos |
| Bridgebio Pharma, INC. | $38.49 | 2025 | Attruby |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.